Clindamycin - Revision history

Danbot: Strip excess bold text

2026-03-22T09:09:29Z

Strip excess bold text

← Older revision		Revision as of 09:09, 22 March 2026
Line 6:		Line 6:
	==Adult Dosing==		==Adult Dosing==
	===General===		===General===
	*~~'''~~PO:~~'''~~		*PO:
	**150-450mg PO q6h		**150-450mg PO q6h
	**First Dose: 150-450mg PO x 1		**First Dose: 150-450mg PO x 1
	**Max: 450mg/dose PO (increased risk of [[C. diff]] at higher doses)		**Max: 450mg/dose PO (increased risk of [[C. diff]] at higher doses)
	*~~'''~~IM:~~'''~~		*IM:
	**1200-2700mg/day IM divided q6-12h		**1200-2700mg/day IM divided q6-12h
	**First Dose: 600mg IM x 1		**First Dose: 600mg IM x 1
	**Max: 600mg/dose IM		**Max: 600mg/dose IM
	*~~'''~~IV~~'''~~		*IV
	**1200-2700mg/day IV divided q6-12h		**1200-2700mg/day IV divided q6-12h
	**First Dose: 600-900mg IV x 1		**First Dose: 600-900mg IV x 1
Line 33:		Line 33:
	==Pediatric Dosing==		==Pediatric Dosing==
	===General Infection (Severe)===		===General Infection (Severe)===
	*~~'''~~<1 week old~~'''~~		*<1 week old
	**''<2kg''		**''<2kg''
	***10mg/kg/day IM/IV divided q12		***10mg/kg/day IM/IV divided q12
Line 40:		Line 40:
	***15mg/kg/day IM/IV divided q8h		***15mg/kg/day IM/IV divided q8h
	***First Dose: 5mg/kg IM/IV x 1		***First Dose: 5mg/kg IM/IV x 1
	*~~'''~~1 week - 1 month~~'''~~		*1 week - 1 month
	**''<1.2kg''		**''<1.2kg''
	***10mg/kg/day IM/IV divided q12h		***10mg/kg/day IM/IV divided q12h
Line 51:		Line 51:
	***Alt: 30mg/kg/day IM/IV divided q6h		***Alt: 30mg/kg/day IM/IV divided q6h
	***First Dose: 5-7.5mg/kg IM/IV x 1		***First Dose: 5-7.5mg/kg IM/IV x 1
	*~~'''~~>1 Month - Children~~'''~~		*>1 Month - Children
	**25-40mg/kg/day IM/IV divided q6-8h		**25-40mg/kg/day IM/IV divided q6-8h
	**First Dose: 6.25-13.3mg/kg IM/IV x 1		**First Dose: 6.25-13.3mg/kg IM/IV x 1
	**Max: 4.8 g/day IM/IV		**Max: 4.8 g/day IM/IV
	*~~'''~~Adolescents~~'''~~		*Adolescents
	**25-40mg/kg/day IM/IV divided q6-8h		**25-40mg/kg/day IM/IV divided q6-8h
	**First Dose: 6.25-13.3mg/kg IM/IV x 1		**First Dose: 6.25-13.3mg/kg IM/IV x 1
Line 61:		Line 61:

	===General Infection (Mild-Moderate)===		===General Infection (Mild-Moderate)===
	*~~'''~~Infants & Children~~'''~~		*Infants & Children
	**~~'''~~PO:~~'''~~		**PO:
	***10-25mg/kg/day PO divided q6-8h		***10-25mg/kg/day PO divided q6-8h
	***First Dose: 2.5-8.3mg/kg PO x 1		***First Dose: 2.5-8.3mg/kg PO x 1
	***Max: 1.8 g/day PO		***Max: 1.8 g/day PO
	**~~'''~~IM/IV:~~'''~~		**IM/IV:
	***15-25mg/kg/day IM/IV divided q6-8		***15-25mg/kg/day IM/IV divided q6-8
	***First Dose: 3.75-8.3mg/kg IM/IV x 1		***First Dose: 3.75-8.3mg/kg IM/IV x 1
	***4.8 g/day IM/IV		***4.8 g/day IM/IV
	*~~'''~~Adolescents~~'''~~		*Adolescents
	**~~'''~~PO:~~'''~~		**PO:
	***150-300mg PO q6h		***150-300mg PO q6h
	***First Dose: 150-300mg PO x 1		***First Dose: 150-300mg PO x 1
	***Max: 1.8 g/day PO		***Max: 1.8 g/day PO
	**~~'''~~IM/IV:~~'''~~		**IM/IV:
	***25-40mg/kg/day IM/IV divided q6-8h		***25-40mg/kg/day IM/IV divided q6-8h
	***First Dose: 6.25-13.3mg/kg IM/IV x 1		***First Dose: 6.25-13.3mg/kg IM/IV x 1
Line 141:		Line 141:

	==Administration==		==Administration==
	*~~'''~~PO: ~~'''~~		*PO:
	**Give with full glass of water (minimize esophageal ulceration)		**Give with full glass of water (minimize esophageal ulceration)
	**Give spread around the day to promote constant serum levels		**Give spread around the day to promote constant serum levels
	*~~'''~~IM:~~'''~~		*IM:
	**Give to deep I.M. sites		**Give to deep I.M. sites
	**Rotate sites		**Rotate sites
	**Do not exceed 600mg per injection		**Do not exceed 600mg per injection
	*~~'''~~IV:~~'''~~		*IV:
	**Do NOT give as bolus		**Do NOT give as bolus
	**Give by intermittent infusion over >10-60 minutes		**Give by intermittent infusion over >10-60 minutes

Danbot: Remove disease-specific entries now covered by AntibioticDose (2 sections)

2026-03-20T11:07:38Z

Remove disease-specific entries now covered by AntibioticDose (2 sections)

← Older revision		Revision as of 11:07, 20 March 2026
Line 80:		Line 80:
	***Max: 4.8 g/day IM/IV		***Max: 4.8 g/day IM/IV

	~~===[[Sinusitis]]===~~
	*30-40mg/kg/day PO divided q8h x 10-14 days
	*Use with cefixime or cefpodoxime

	~~===[[Streptococcal Pharyngitis]]===~~
	*7mg/kg/dose PO q8h x 10 days<ref>CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>
	*Max: 300mg/dose

	===Indications by Disease===		===Indications by Disease===

Danbot: Remove disease-specific dosing covered by dynamic SMW tables; keep general/uncovered entries

2026-03-20T02:56:57Z

Remove disease-specific dosing covered by dynamic SMW tables; keep general/uncovered entries

@@ Line 18: / Line 18: @@
 **First Dose: 600-900mg IV x 1
 **4800mg/day IV
 ===Indications by Disease===
@@ Line 100: / Line 79: @@
 ***First Dose: 6.25-13.3mg/kg IM/IV x 1
 ***Max: 4.8 g/day IM/IV
 ===[[Sinusitis]]===
@@ Line 119: / Line 87: @@
 *7mg/kg/dose PO q8h x 10 days<ref>CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>
 *Max: 300mg/dose
 ===Indications by Disease===

Danbot: Restore original dosing content alongside dynamic SMW tables

2026-03-20T02:37:00Z

Restore original dosing content alongside dynamic SMW tables

Show changes

Danbot: Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

2026-03-20T01:51:27Z

Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

@@ Line 5: / Line 5: @@
 ==Adult Dosing==
-===General===
+===Indications by Disease===
-*'''PO:'''
+{{#ask: [[Has DrugName::Clindamycin]] [[Has Population::Adult]]
-**150-450mg PO q6h
+|?Treats disease=Disease
-**First Dose: 150-450mg PO x 1
+|?Has Dose=Dose
-**Max: 450mg/dose PO (increased risk of [[C. diff]] at higher doses)
+|?Has Context=Context
-*'''IM:'''
+|format=table
-**1200-2700mg/day IM divided q6-12h
+|limit=50
-**First Dose: 600mg IM x 1
+|mainlabel=-
-**Max: 600mg/dose IM
+|headers=show
-*'''IV'''
+|sort=Treats disease
-**1200-2700mg/day IV divided q6-12h
+}}
 ==Pediatric Dosing==
-===General Infection (Severe)===
+===Indications by Disease===
-*'''<1 week old'''
+{{#ask: [[Has DrugName::Clindamycin]] [[Has Population::Pediatric]]
-**''<2kg''
+|?Treats disease=Disease
-***10mg/kg/day IM/IV divided q12
+|?Has Dose=Dose
-***First Dose: 5mg/kg IM/IV x 1
+|?Has Context=Context
-**''>2kg''
+|format=table
-***15mg/kg/day IM/IV divided q8h
+|limit=50
-***First Dose: 5mg/kg IM/IV x 1
+|mainlabel=-
-*'''1 week - 1 month'''
+|headers=show
-**''<1.2kg''
+|sort=Treats disease
-***10mg/kg/day IM/IV divided q12h
+}}
 ==Special Populations==

Rossdonaldson1: /* Streptococcal Pharyngitis */

2026-01-28T18:39:45Z

Streptococcal Pharyngitis

← Older revision		Revision as of 18:39, 28 January 2026
Line 104:		Line 104:

	===[[Streptococcal Pharyngitis]]===		===[[Streptococcal Pharyngitis]]===
	*7mg/kg PO q8h x 10 days		*7mg/kg/dose PO q8h x 10 days<ref>CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>
	*Max: 300mg/dose		*Max: 300mg/dose

Rossdonaldson1: /* Strep. Pharyngitis */

2026-01-28T18:39:01Z

Strep. Pharyngitis

← Older revision		Revision as of 18:39, 28 January 2026
Line 23:		Line 23:

	===[[Strep. Pharyngitis]]===		===[[Strep. Pharyngitis]]===
	*300mg PO q8 x 10 days		*300mg PO q8 x 10 days<ref>CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>

	===[[Bacterial Vaginosis]]===		===[[Bacterial Vaginosis]]===

Elcatracho: /* Administration */

2021-03-06T13:10:05Z

Administration

← Older revision		Revision as of 13:10, 6 March 2021
Line 175:		Line 175:
	**Max rate: 30mg/minute (do not exceed 1200mg/hour)		**Max rate: 30mg/minute (do not exceed 1200mg/hour)
	**Final concentration should not exceed 18mg/mL		**Final concentration should not exceed 18mg/mL

			==Mechanism of Action==
			*Disrupts protein synthesis by binding the 50s ribosome subunit

	==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==		==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==

Hoxbox: /* Cellulitis Possibly due to MRSA (Unlabled Use)Liu C, Bayer A, Cosgrove SE, et al, “Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and...

2020-03-05T15:47:00Z

/* Cellulitis Possibly due to MRSA (Unlabled Use)Liu C, Bayer A, Cosgrove SE, et al, “Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and...

← Older revision		Revision as of 15:47, 5 March 2020
Line 20:		Line 20:

	===[[Cellulitis]] Possibly due to [[MRSA]] (Unlabled Use)<ref>Liu C, Bayer A, Cosgrove SE, et al, “Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary,” Clin Infect Dis, 2011, 52(3):285-92. PubMed 21217178</ref>===		===[[Cellulitis]] Possibly due to [[MRSA]] (Unlabled Use)<ref>Liu C, Bayer A, Cosgrove SE, et al, “Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary,” Clin Infect Dis, 2011, 52(3):285-92. PubMed 21217178</ref>===
	*300-~~450mg PO q8hr x 5~~-10 ~~days~~		*60-120 kg: 300 mg Q8H. >120kg: 450 mg Q8H. <ref>Reduction of Inappropriate Antibiotic Use and Improved Outcomes by Implementation of an Algorithm-Based Clinical Guideline for Nonpurulent Skin and Soft Tissue Infections. Ann Emerg Med. 2020 Feb 13. pii: S0196-0644(19)31453-2. doi: 10.1016/j.annemergmed.2019.12.012. [Epub ahead of print]</ref>

	===[[Strep. Pharyngitis]]===		===[[Strep. Pharyngitis]]===

ClaireLewis at 17:39, 20 September 2019

2019-09-20T17:39:40Z

← Older revision		Revision as of 17:39, 20 September 2019
Line 1:		Line 1:
	==General==		==General==
	*Type: Other ~~antibiotics~~		*Type: Other [[antibiotic]]
	*Dosage Forms: IM, IV, PO (75mg; 150mg; 300mg; 75mg/5mL)		*Dosage Forms: IM, IV, PO (75mg; 150mg; 300mg; 75mg/5mL)
	*Common Trade Names: Cleocin		*Common Trade Names: Cleocin
Line 304:		Line 304:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:ID]]